

Table S2. Percentage of hyper Vif derivatives in stable A3H humanized mice co-inoculated with hyper and hypo HIV-1s.

| Mouse no.* | Donor lot* | <i>APOBE3H</i> haplotype | | # Analyzed sequence | # Hyper Vif derivatives | % Hyper Vif derivatives | #Hypo Vif derivatives | % Hypo Vif derivatives | # Hypo Vif derivatives with anti-A3H activity† | % Vif with anti-A3H-II activity‡ |
|----------------|------------|--------------------------|--------|---------------------|-------------------------|-------------------------|-----------------------|------------------------|--|----------------------------------|
| 1 | A | III / V | Stable | 38 | 35 | 92.1 | 3 | 7.9 | 1 | 94.7 |
| 2 | A | III / V | Stable | 64 | 40 | 62.5 | 24 | 37.5 | 1 | 64.1 |
| 3 | B | I / II | Stable | 52 | 30 | 57.7 | 22 | 42.3 | 1 | 59.6 |
| 4 | B | I / II | Stable | 49 | 43 | 87.8 | 6 | 12.2 | 0 | 87.8 |
| 5 | B | I / II | Stable | 52 | 17 | 32.7 | 35 | 67.3 | 23 | 76.9 |
| 6 | B | I / II | Stable | 47 | 44 | 93.6 | 3 | 6.4 | 0 | 93.6 |
| 7 | B | I / II | Stable | 40 | 34 | 85.0 | 6 | 15.0 | 2 | 90.0 |
| 8 | B | I / II | Stable | 49 | 43 | 87.8 | 6 | 12.2 | 0 | 87.8 |
| Average | | | | 391 | 286 | 73.1 | 105 | 26.9 | 28 | 80.3 |
| SEM | | | | | | 7.7 | | 7.7 | | 4.8 |

* Identical to Figure 1 and Table S1.

† Number of hyper Vif derivatives acquiring anti-A3H-II activity (Figures 1E-1G).

‡ Percentage of hyper Vif derivatives and the hyper Vif derivatives acquiring anti-A3H-II activity.